High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- 31 March 2016
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 59, 152-159
- https://doi.org/10.1016/j.ejca.2016.03.002
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Novel drugs in clinical development for hepatocellular carcinomaExpert Opinion on Investigational Drugs, 2015
- The Journey from Discoveries in Fundamental Immunology to Cancer ImmunotherapyCancer Cell, 2015
- PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.Cancer Control, 2014
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Immune Regulation of CancerJournal of Clinical Oncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology, 2001
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisNew England Journal of Medicine, 1996